Posted by Michael Wonder on 26 Aug 2019
FDA approves US WorldMeds' Myobloc (rimabotulinumtoxinB) injection for chronic sialorrhea
26 August 2019 - Myobloc is the only approved botulinum toxin for chronic sialorrhoea that provides significant results in as early as one week.
US WorldMeds, LLC announced today that the U.S. FDA approved the supplemental biologics license application for Myobloc (rimabotulinumtoxinB) injection for the treatment of chronic sialorrhoea in adults.
Myobloc, the first and only approved botulinum toxin type B, significantly decreases sialorrhoea symptoms with a single treatment in as early as 1 week and lasts up to 3 months. The approval is supported by multiple clinical trials, including a multi-center, double-blind, placebo-controlled, efficacy and safety study of Myobloc.
